The Experts below are selected from a list of 14982 Experts worldwide ranked by ideXlab platform
Robert Maclaren - One of the best experts on this subject based on the ideXlab platform.
-
Proton Pump Inhibitors for stress ulcer prophylaxis in critically ill patients
Annals of Pharmacotherapy, 2002Co-Authors: Rose Jung, Robert MaclarenAbstract:OBJECTIVE:To evaluate the use of Proton-Pump Inhibitors (PPIs) for stress ulcer prophylaxis in critically ill adults.DATA SOURCES:Computerized biomedical literature search of MEDLINE (1966–June 2002) was conducted using the MeSH headings Proton-Pump inhibitor, ulcer, critical care, and acid. References of selected articles were reviewed. A manual search of critical care, surgery, trauma, gastrointestinal, and pharmacy journals was conducted to identify relevant abstracts.DATA SYNTHESIS:Traditional medications used for stress ulcer prophylaxis include antacids, histamine2 receptor antagonists (H2RAs), and sucralfate. Few studies have evaluated PPIs for stress ulcer prophylaxis. The majority of studies have demonstrated that enteral or intravenous administration of PPIs to critically ill patients elevates intragastric pH and consistently maintains pH ≥4.0. PPIs are safe and seem to be as efficacious as H2RAs or sucralfate for prevention of bleeding from stress-related mucosal damage (SRMD) and they may prov...
-
Proton Pump Inhibitors for stress ulcer prophylaxis in critically ill patients
Annals of Pharmacotherapy, 2002Co-Authors: Rose Jung, Robert MaclarenAbstract:OBJECTIVE:To evaluate the use of Proton-Pump Inhibitors (PPIs) for stress ulcer prophylaxis in critically ill adults.DATA SOURCES:Computerized biomedical literature search of MEDLINE (1966–June 2002) was conducted using the MeSH headings Proton-Pump inhibitor, ulcer, critical care, and acid. References of selected articles were reviewed. A manual search of critical care, surgery, trauma, gastrointestinal, and pharmacy journals was conducted to identify relevant abstracts.DATA SYNTHESIS:Traditional medications used for stress ulcer prophylaxis include antacids, histamine2 receptor antagonists (H2RAs), and sucralfate. Few studies have evaluated PPIs for stress ulcer prophylaxis. The majority of studies have demonstrated that enteral or intravenous administration of PPIs to critically ill patients elevates intragastric pH and consistently maintains pH ≥4.0. PPIs are safe and seem to be as efficacious as H2RAs or sucralfate for prevention of bleeding from stress-related mucosal damage (SRMD) and they may prov...
Ulrich Klotz - One of the best experts on this subject based on the ideXlab platform.
-
relative potency of Proton Pump Inhibitors comparison of effects on intragastric ph
European Journal of Clinical Pharmacology, 2009Co-Authors: Julia Kirchheiner, Ulrich Klotz, Silke Glatt, Uwe Fuhr, Ingolf Meineke, T Seufferlein, J BrockmollerAbstract:Aim Comparative potency of Proton-Pump Inhibitors (PPIs) is an important clinical issue. Most available trials have compared the different PPIs at one or a few selected specific dosages, making it difficult to derive quantitative equivalence dosages. Here we derived PPI dose equivalents based on a comprehensive assessment of dose-dependent effects on intragastric pH.
-
Proton Pump Inhibitors an update of their clinical use and pharmacokinetics
European Journal of Clinical Pharmacology, 2008Co-Authors: Shaojun Shi, Ulrich KlotzAbstract:Background Proton Pump Inhibitors (PPIs) represent drugs of first choice for treating peptic ulcer, Helicobacter pylori infection, gastrooesophageal reflux disease, nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal lesions (complications), and Zollinger-Ellison syndrome.
-
CYP2C19 Polymorphism and Proton Pump Inhibitors
Basic & clinical pharmacology & toxicology, 2004Co-Authors: Ulrich Klotz, Matthias Schwab, Gerhard TreiberAbstract:Proton Pump Inhibitors such as omeprazole (esomeprazole), lansoprazole, pantoprazole and rabeprazole are eliminated by the hepatic route and the polymorphic CYP2C19 is mainly involved in their metabolism. In different populations three phenotypes have been identified: extensive metabolizers, poor metabolizers and individuals carrying one wild type and one mutant allele (het extensive metabolizers). Systemic exposure to the Proton Pump Inhibitors as expressed by the AUC (area under the plasma level time profiles) is 5-12-times higher in poor metabolizers than in extensive metabolizers. As the pharmacodynamic response (elevation of intragastric pH) to the Proton Pump Inhibitors is related directly to their AUC, a much higher pH can be monitored over 24 hr in poor metabolizers than in extensive metabolizers. Furthermore, clinical efficacy of all Proton Pump Inhibitors depend on maintaining intragastric pH above certain threshold levels and significantly higher eradication rates of Helicobacter pylori have been observed in patients of the poor metabolizers and het extensive metabolizers phenotype if compared to extensive metabolizers. Likewise, limited data suggest that Proton Pump Inhibitors-induced healing rates in gastro-oesophageal reflux disease are apparently higher in poor metabolizers/het extensive metabolizers than in extensive metabolizers of CYP2C19. Therefore initial genotyping for this enzyme and higher dosage in extensive metabolizers is likely to improve the clinical efficacy of Proton Pump Inhibitors.
Deborah J Cook - One of the best experts on this subject based on the ideXlab platform.
-
Proton Pump Inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients a systematic review and meta analysis
Critical Care Medicine, 2013Co-Authors: Waleed Alhazzani, Paul Moayyedi, Farhan Alenezi, Roman Jaeschke, Deborah J CookAbstract:Background:Critically ill patients may develop bleeding caused by stress ulceration. Acid suppression is commonly prescribed for patients at risk of stress ulcer bleeding. Whether Proton Pump Inhibitors are more effective than histamine 2 receptor antagonists is unclear.Objectives:To determine the e
Joseph R. Pisegna - One of the best experts on this subject based on the ideXlab platform.
-
the role of Proton Pump Inhibitors in the treatment of zollinger ellison syndrome
Expert Opinion on Pharmacotherapy, 2006Co-Authors: Jose M Nieto, Joseph R. PisegnaAbstract:Zollinger-Ellison syndrome is characterised by refractory peptic ulcer disease, diarrhoea and gastric acid hypersecretion associated with a gastrin-secreting tumour. The incidence is unknown, but, in the US, the frequency is 0.1-3.0 million people. Zollinger-Ellison syndrome is associated with multiple endocrine neoplasia type 1 in 25-35% of the cases. The diagnosis of Zollinger-Ellison syndrome is suggested when plasma gastrin is > 1000 pg/ml and the basal acid output is > 15 mEq/h or when associated with a pH < 2. The treatment is focused on controlling gastric acid hypersecretion and localisation of the tumour and its metastases. Proton Pump Inhibitors are the most effective antisecretory drugs and can be administered at high dosages. This review focuses on the role of the Proton Pump Inhibitors in the management of gastric acid hypersecretion in Zollinger-Ellison syndrome.
-
replacement of oral Proton Pump Inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with zollinger ellison syndrome
The American Journal of Gastroenterology, 2001Co-Authors: David C Metz, Elaine Soffer, Chris E Forsmark, Wieslaw J Bochenek, Edward A Lew, Julie Starr, Joseph R. PisegnaAbstract:Replacement of oral Proton Pump Inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome
Paul Moayyedi - One of the best experts on this subject based on the ideXlab platform.
-
Proton Pump Inhibitors for functional dyspepsia
Cochrane Database of Systematic Reviews, 2017Co-Authors: Maria Ines Pintosanchez, Yuhong Yuan, Premysl Bercik, Paul MoayyediAbstract:Background Functional dyspepsia (FD or non‐ulcer dyspepsia) is defined as continuous or frequently recurring epigastric pain or discomfort for which no organic cause can be found. Acid suppressive therapy, including Proton Pump Inhibitors (PPIs), has been proposed as a therapeutic option in FD, but its efficacy remains controversial. While PPIs are generally considered safe and well tolerated, they have been associated with adverse events, especially in the long term. For this reason, decisions on whether to initiate or continue PPI therapy should be made based on an appropriate clinical indication. Therefore, we conducted a systematic review to evaluate whether PPI therapy provides symptomatic relief in FD.
-
Proton Pump Inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients a systematic review and meta analysis
Critical Care Medicine, 2013Co-Authors: Waleed Alhazzani, Paul Moayyedi, Farhan Alenezi, Roman Jaeschke, Deborah J CookAbstract:Background:Critically ill patients may develop bleeding caused by stress ulceration. Acid suppression is commonly prescribed for patients at risk of stress ulcer bleeding. Whether Proton Pump Inhibitors are more effective than histamine 2 receptor antagonists is unclear.Objectives:To determine the e
-
diagnostic and therapeutic use of Proton Pump Inhibitors in non cardiac chest pain a metaanalysis
The American Journal of Gastroenterology, 2005Co-Authors: Filippo Cremonini, James L Wise, Paul Moayyedi, Nicholas J TalleyAbstract:Diagnostic and Therapeutic Use of Proton Pump Inhibitors in Non-Cardiac Chest Pain: A Metaanalysis
